Skip to main content
RELYVRIO™ Logo
RELYVRIO™ Logo

Helpful support and resources for you and 
your patients

 

The Amylyx Care Team (ACT)™ helps provide support and resources for people taking RELYVRIO™

Healthcare Professional icon

Support for you

ACT team members can help:

  • Investigate insurance benefits
  • Explain the prior authorization (PA) process and follow up on the status of submitted PAs
  • Explore financial assistance options for eligible patients
  • Coordinate medication fulfillment with specialty pharmacies
Taylor, ACT Care Support Specialist
Taylor ACT Care Support Specialist
Patient icon

Support for your patients

When you enroll a patient in the ACT Support Program you provide them with:

  • Personalized support to help your patients throughout their care journey with RELYVRIO
  • A RELYVRIO prescription

Your patients will receive one-on-one support from a single source—their dedicated ACT Care Coordinator

Enroll a Patient Now

Helpful tips when getting patients started:

  • When you fill out an enrollment form for your patients, it will serve as a prescription and bring them into the ACT Support Program
  • RELYVRIO will be available through specialty pharmacies, which can deliver the therapy right to the patient’s home
  • Since RELYVRIO is a newly approved specialty product, it may take time to get the therapy to your patients. This is a normal part of the process for new specialty products
  • ACT will communicate updates to you and your patients to help them get access as soon as possible
Ouriel Filho headshot
Priscilla Robertson headshot
Sunshine Wylie headshot

Our team of specialists can help patients get started and continue on RELYVRIO treatment as prescribed

Visit ACT Today

Or call 866-318-2989
 • Monday-Friday, 8 AM to 8 PM ET

Download Resources to Help Your Patients Get Started on RELYVRIO Therapy

HCP Resources

Patient Resources

Learn about the RELYVRIO function and post-hoc survival data

Explore the Data

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk in Patients With Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders

RELYVRIO contains taurursodiol, which is a bile acid. In patients with disorders that interfere with bile acid circulation, there may be an increased risk for worsening diarrhea, and patients should be monitored appropriately for this adverse reaction. Pancreatic insufficiency, intestinal malabsorption, or intestinal diseases that may alter the concentration of bile acids may also lead to decreased absorption of either of the components of RELYVRIO. Because different enterohepatic circulation, pancreatic, and intestinal disorders have varying degrees of severity, consider consulting with a specialist. Patients with disorders of enterohepatic circulation (eg, biliary infection, active cholecystitis), severe pancreatic disorders (eg, pancreatitis), and intestinal disorders that may alter concentrations of bile acids (eg, ileal resection, regional ileitis) were excluded from the study; therefore, there is no clinical experience in these conditions.

Use in Patients Sensitive to High Sodium Intake

RELYVRIO has a high salt content. Each initial daily dosage of 1 packet contains 464 mg of sodium; each maintenance dosage of 2 packets daily contains 928 mg of sodium. In patients sensitive to salt intake (eg, those with heart failure, hypertension, or renal impairment), consider the amount of daily sodium intake in each dose of RELYVRIO and monitor appropriately.

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

The most common adverse reactions (at least 15% and at least 5% greater than placebo) with RELYVRIO were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first 3 weeks of treatment.

You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

For more information about RELYVRIO, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk in Patients With Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders

RELYVRIO contains taurursodiol, which is a bile acid. In patients with disorders that interfere with bile acid circulation, there may be an increased risk for worsening diarrhea, and patients should be monitored appropriately for this adverse reaction. Pancreatic insufficiency, intestinal malabsorption, or intestinal diseases that may alter the concentration of bile acids may also lead to decreased absorption of either of the components of RELYVRIO. Because different enterohepatic circulation, pancreatic, and intestinal disorders have varying degrees of severity, consider consulting with a specialist. Patients with disorders of enterohepatic circulation (eg, biliary infection, active cholecystitis), severe pancreatic disorders (eg, pancreatitis), and intestinal disorders that may alter concentrations of bile acids (eg, ileal resection, regional ileitis) were excluded from the study; therefore, there is no clinical experience in these conditions.

Use in Patients Sensitive to High Sodium Intake

RELYVRIO has a high salt content. Each initial daily dosage of 1 packet contains 464 mg of sodium; each maintenance dosage of 2 packets daily contains 928 mg of sodium. In patients sensitive to salt intake (eg, those with heart failure, hypertension, or renal impairment), consider the amount of daily sodium intake in each dose of RELYVRIO and monitor appropriately.

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

The most common adverse reactions (at least 15% and at least 5% greater than placebo) with RELYVRIO were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first 3 weeks of treatment.

You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

For more information about RELYVRIO, please see the full Prescribing Information.